8th wave of Covid-19: who can be vaccinated, where, when and with which vaccines?

8th wave of Covid 19 who can be vaccinated where when

The resumption of the Covid-19 epidemic is confirmed in France. The reproduction rate of the virus, the famous R, has risen above 1, the robust signal that the epidemic is progressing. The number of new cases is increasing: 51,816 positive cases were identified in 24 hours on Tuesday September 20, against 41,850 a week ago, or +23.8%. The rolling average is close to 30,000 cases per day, and it is up 47% over one week.

In the arsenal of the fight against the coronavirus, the health authorities now have the latest generation vaccines, adapted to the new variants. In France, the High Authority for Health (HAS) on Tuesday gave the green light to three latest generation vaccines, adapted to Omicron, for a new recall campaign in the fall, coupled with that against the flu.

Update on vaccination in France, at the dawn of a possible eighth wave, due to an immune decline in a population which has sometimes been contaminated or received its last vaccine many months ago.

  • Who can get vaccinated?

People aged 60 or over, and those under 60 at risk of a severe form of Covid-19 (people with comorbidities, pregnant women from the first trimester of pregnancy, immunocompromised people, children and adolescents at high risk), those around them, and professionals in the health and medico-social sector can receive a second booster dose.

All people eligible for a second booster dose can do so from three months after the first booster for people aged 80 and over, as well as for residents of nursing homes, those in long-term care units (USLD) and severely immunocompromised people, whatever their age and from 6 months after the first booster for other eligible people.

People eligible for the second booster dose of the Covid-19 vaccine.

People eligible for the second booster dose of the Covid-19 vaccine.

Ministry of Health screenshot

As of September 19, according to figures from Public Health France, only 20.6% of 60-64 year olds, and 36.4% of people aged 80 and over, have received a second booster dose of vaccination, while 85.4% of people aged 65 or over have had a booster vaccination.

In addition, anyone who has not received their first booster dose can make an appointment to be vaccinated, if they wish.

  • Where can you get vaccinated?

Vaccination is now mainly done in the city. People who wish to receive their second booster dose are invited to contact their doctor, their nurse, their pharmacist or to go to the vaccination centers, some of which remain open. You can also make an appointment via www.sante.fr.

  • What vaccines can we receive?

In France, the HAS recommended “preferably” Tuesday the use of bivalent vaccines for a vaccination campaign in the fall. These are the vaccines from Moderna and Pfizer/BioNTech targeting the original strain of the virus and the BA.1 variant of Omicron, and the vaccine from Pfizer/BioNTech targeting the original strain and the BA subvariants .4 and BA.5 from Omicron. These vaccines were validated in early September by the European Medicines Agency. They use messenger RNA technology, like almost all of the vaccines used until now. “These are not new vaccines but vaccines adapted to circulating strains”, underlined the HAS.

For the new reminder campaign against Covid-19, the HAS has maintained its recommendation to couple it with the annual flu vaccination, which will start on October 18. A concomitant injection or the same day of the two vaccines is possible, she recalled. “In the immediate term and because the number of cases of infections has started to rise again for a few days”, those most at risk are invited not to wait to receive their second reminder, if they have not yet received it. had. This recommendation applies regardless of the anti-Covid vaccine initially administered to the person.

Bivalent vaccines, of which France has already ordered several million, should be quickly available in vaccination centers and pharmacies. Orders from the Sanofi (monovalent Beta) and Spanish Hipra (bivalent Alpha-Beta) laboratories, whose vaccines are still being studied by the European Medicines Agency, have also been placed, but they are not expected before the end of the month. year, according to the Directorate General of Health.

If we compare to the original vaccines, “the expected clinical efficacy of the new bivalent vaccines is at least equivalent or even superior”, and their tolerance is “identical”, according to the HAS. The original version of the vaccine (monovalent) based on the original strain of the virus remains effective against severe forms, hospitalizations and deaths associated with the disease, hammer the health authorities. And it is the only possible for a first vaccination, notes the HAS.